Table 1

Characteristics of patients in this study

CD

UC

HS

Indeterminate


n

121

75

27

8

Female gender (n)

59.5% (72)

49.3% (37)

55.6% (15)

62.5% (5)

Age (lower 95%-upper 95%)

37.3 (34.3-40.3)

41.1 (37.4-44.9)

35.1 (29.1-41.2)

26.9 (13.4-40.3)

Smoker (n)

Never

63.6% (77)

57.3% (43)

85.2% (23)

75.0% (6)

Previously

24.8% (30)

40% (30)

11.1% (3)

12.5% (1)

Current

10.7% (13)

2.7% (2)

0% (0)

12.5% (1)

Unknown

0.8% (1)

0% (0)

3.7% (1)

0% (0)

Sample

Stool (n)

51.2% (62)

64% (48)

66.7% (18)

100% (8)

Biopsy (n)

48.8% (59)

36% (27)

33.3% (9)

0% (0)

Disease

Active disease (n)a

26.4% (32)

29.3% (22)

0% (0)

0% (0)

Ileal (n)

35.5% (43)

NA

NA

NA

Treatment

Mesalamine (n)

55.4% (67)

77.3% (58)

0% (0)

75.0% (6)

Steroids (n)

31.4% (38)

37.3% (28)

0% (0)

50% (4)

Immunosuppressant (n)b

38.8% (47)

16% (12)

0% (0)

0% (0)

Antibiotics (n)

12.4% (15)

13.3% (10)

0% (0)

12.5% (1)


aActive disease defined by a Harvey-Bradshaw Index (HBI) ≥ 5 or Pediatric Crohn's Disease Activity Index (pCDAI) ≥ 10 for Crohn's disease (CD), and Simple Clinical Colitis Activity Index ≥ 5 or Pediatric Ulcerative Colitis Activity Index (pUCAI) ≥ 10 for ulcerative colitis (UC). bImmunosuppressant treatments include thiopurines, methotrexate, and anti-tumor necrosis factor-α antibody. HS, healthy subjects; NA, not applicable.

Morgan et al. Genome Biology 2012 13:R79   doi:10.1186/gb-2012-13-9-r79

Open Data